2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2895

Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish
Abstract Number: 2896

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers
Abstract Number: 2897

Microvascular Function in Systemic Sclerosis Patients with End-Stage Vascular Manifestations of the Disease
Abstract Number: 2898

Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis: Is Empiric Use of Proton Pump Inhibitors Supported?
Abstract Number: 2899

Impact of the Clinical Characteristics of Systemic Sclerosis in Patients Quality of Life
Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey
Abstract Number: 2901

SSc and the Significance of Blood Group Antigens
Abstract Number: 2902

Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Abstract Number: 2903

Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up
Abstract Number: 2904

Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients
Abstract Number: 2905

Predictors of Poor Hand Function in Systemic Sclerosis
Abstract Number: 2906

The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience
Abstract Number: 2907

Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Abstract Number: 2908

Anti-Vinculin Antibodies: A Novel Biomarker in Systemic Sclerosis, and Its Association with Vascular Involvement
Abstract Number: 2909

Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].